Evidence map›Paper›PMID 29186865›Full record

ArticleInternational journal of molecular sciences2017

Role of Vitamin D in Maintaining Renal Epithelial Barrier Function in Uremic Conditions.

Milos Mihajlovic, Michele Fedecostante, Miriam J Oost, Sonja K P Steenhuis, Eef G W M Lentjes, Inge Maitimu-Smeele, Manoe J Janssen, Luuk B Hilbrands, Rosalinde Masereeuw

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. The role of claudins in homeostasis.Nature reviews. Nephrology · 2023
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. The Effects of Vitamins and Micronutrients onJournal of immunology research · 2022
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Milos MihajlovicDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands. m.mihajlovic@uu.nl.ORCID 0000-0001-6120-5200
Michele FedecostanteDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands. m.fedecostante@uu.nl.ORCID 0000-0002-9032-6711
Miriam J OostDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands. m.j.oost@students.uu.nl.
Sonja K P SteenhuisDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands. s.k.p.steenhuis@students.uu.nl.
Eef G W M LentjesDepartment of Clinical Chemistry and Haematology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands. egwm.lentjes@umcutrecht.nl.ORCID 0000-0003-4055-2291
Inge Maitimu-SmeeleDepartment of Clinical Chemistry and Haematology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands. imaitimu@umcutrecht.nl.
Manoe J JanssenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands. m.j.janssen1@uu.nl.
Luuk B HilbrandsDepartment of Nephrology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands. luuk.hilbrands@radboudumc.nl.
Rosalinde MasereeuwDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands. r.masereeuw@uu.nl.ORCID 0000-0002-1560-1074
Utrecht University · NLUniversity Medical Center Utrecht · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As current kidney replacement therapies are not efficient enough for end-stage renal disease (ESRD) treatment, a bioartificial kidney (BAK) device, based on conditionally immortalized human proximal tubule epithelial cells (ciPTEC), could represent an attractive solution. The active transport activity of such a system was recently demonstrated. In addition, endocrine functions of the cells, such as vitamin D activation, are relevant. The organic anion transporter 1 (OAT-1) overexpressing ciPTEC line presented 1α-hydroxylase (CYP27B1), 24-hydroxylase (CYP24A1) and vitamin D receptor (VDR), responsible for vitamin D activation, degradation and function, respectively. The ability to produce and secrete 1α,25-dihydroxy-vitamin D₃, was shown after incubation with the precursor, 25-hydroxy-vitamin D₃. The beneficial effect of vitamin D on cell function and behavior in uremic conditions was studied in the presence of an anionic uremic toxins mixture. Vitamin D could restore cell viability, and inflammatory and oxidative status, as shown by cell metabolic activity, interleukin-6 (IL-6) levels and reactive oxygen species (ROS) production, respectively. Finally, vitamin D restored transepithelial barrier function, as evidenced by decreased inulin-FITC leakage in biofunctionalized hollow fiber membranes (HFM) carrying ciPTEC-OAT1. In conclusion, the protective effects of vitamin D in uremic conditions and proven ciPTEC-OAT1 endocrine function encourage the use of these cells for BAK application.

Indexed as

25-Hydroxyvitamin D3 1-alpha-HydroxylaseCell LineCell SurvivalCytoprotectionEpithelial CellsHumansInterleukin-6Kidney Tubules, ProximalOrganic Anion Transport Protein 1Oxidative StressReceptors, CalcitriolToxins, BiologicalVitamin DVitamin D3 24-HydroxylaseVitamins25-Hydroxyvitamin D3 1-alpha-HydroxylaseCYP24A1 protein, humanCYP27B1 protein, humanInterleukin-6Organic Anion Transport Protein 1Receptors, CalcitriolToxins, Biologicaluremia middle molecule toxinsVitamin DVitamin D3 24-HydroxylaseVitaminsbioartificial kidneychronic kidney diseaseconditionally immortalized proximal tubule cellsend-stage renal diseaseepithelial barrieruremic toxinsvitamin D

Identifiers

PMID29186865
PMCPMC5751134
OpenAlexW2768562036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.